Getty Realty Formalizes 4M Share Offering via Forward Sale Agreements

summarizeSummary

Getty Realty Corp. entered into definitive agreements for its common stock offering, utilizing a forward sale structure to raise capital for acquisitions and debt repayment at a favorable future price.

check_boxKey Events

• Definitive Offering Agreements Executed

  Getty Realty Corp. entered into an Underwriting Agreement and separate Forward Sale Agreements on February 17, 2026, formalizing its previously announced common stock offering.

• Offering Size and Pricing

  The offering involves 4 million shares of common stock, with underwriters holding a 30-day option to purchase an additional 600,000 shares. The company expects to receive proceeds of $32.48 per share upon future settlement of the forward sale agreements.

• Forward Sale Structure Details

  The company will not receive immediate proceeds from the initial sale of shares by the forward sellers. Instead, it anticipates receiving cash upon physical settlement of the forward sale agreements within approximately one year, creating a deferred dilution scenario.

• Use of Proceeds

  The net proceeds from the future settlement are intended to fund property acquisitions, repay indebtedness under the company's revolving credit facility, and for general working capital and corporate purposes.

auto_awesomeAnalysis

This 8-K formalizes the definitive agreements for Getty Realty Corp.'s previously announced common stock offering. While the offering represents substantial potential dilution (up to 7.95% of current market cap), the forward sale agreement structure allows the company to defer the issuance of shares and receipt of cash for up to one year. The company is set to receive proceeds at $32.48 per share upon future settlement, which is a favorable price compared to the current market price of $31.80 and the public offering price of $32.00. The strategic use of proceeds for property acquisitions, debt repayment, and working capital is positive for a REIT, aiming to strengthen the balance sheet and support growth. Investors should consider the long-term benefits of capital infusion against the future dilutive impact.